ADCT
ADCT
NYSE · Biotechnology

Adc Therapeutics Sa

$1.09
-0.02 (-1.80%)
As of Jun 21, 10:20 PM ET ·
Financial Highlights (FY 2026)
Revenue
84.54M
Net Income
-148,197,815
Gross Margin
92.9%
Profit Margin
-175.3%
Rev Growth
-27.1%
D/E Ratio
3.72
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 92.9% 92.9% 56.3% 56.3%
Operating Margin -149.3% -134.4% 17.5% 15.8%
Profit Margin -175.3% -166.5% 14.9% 11.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 84.54M 115.96M 66.42M 54.81M
Gross Profit 78.52M 107.69M 37.41M 30.87M
Operating Income -126,256,513 -155,850,859 11.64M 8.67M
Net Income -148,197,815 -182,935,171 9.87M 6.47M
Gross Margin 92.9% 92.9% 56.3% 56.3%
Operating Margin -149.3% -134.4% 17.5% 15.8%
Profit Margin -175.3% -166.5% 14.9% 11.8%
Rev Growth -27.1% -27.1% +3.3% +12.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 54.62M 54.62M 206.57M 213.23M
Total Equity 14.70M 14.70M 282.56M 265.87M
D/E Ratio 3.72 3.72 0.73 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -125,513,937 -163,541,681 12.50M 10.42M
Free Cash Flow 3.90M 4.50M